Burning Issues Cannabis Radio

Today on Burning Issues Dr. Mitch is Joined by ​​Franjo Grotenhermen, MD. Franjo has devoted the last 15 years of his career to the investigation of scientific and policy issues related to the medicinal and recreational use of cannabis and cannabinoids. Dr. Grotenhermen is founder and chairman of the Association for Cannabis as Medicine (ACM) and founder and executive director of the International Association for Cannabis as Medicine (IACM) (www.cannabis-med.org). The ACM was founded in 1997 by physicians, patients and others advocating the medical use of cannabis. Its members are from the German speaking countries. The ACM formed the basis of the International Association for Cannabis as Medicine (IACM), a scientific association, which serves as a global clearinghouse for science-based information on the medicinal uses of cannabis and continues to provide information to other researchers, patients, pharmaceutical firms, policy makers, and the media. He is editor of the IACM-Bulletin, which is published bi-weekly in six languages (English, German, French, Spanish, Dutch and Italian) and editor of the internet journal CANNABINOIDS, published on the website of the IACM. He is a principal of the nova-Institute based near Cologne and author of many articles, books and book chapters on the therapeutic potential, pharmacology and toxicology of the cannabinoids. He is an expert and consultant on these issues for private persons, companies, courts and institutions, including the World Health Organization.

Today on Burning Issues we talk to David Bearman, M.D. about cannabis treatment for ADD and ADHD. Dr. Bearman is one of the most clinically knowledgeable physicians in the U.S. in the field of medicinal marijuana. He has spent 40 years working in substance and drug abuse treatment and prevention programs. Dr. Bearman was a pioneer in the free and community clinic movement. His career includes public health, administrative medicine, provision of primary care, pain management and cannabinology. His almost 40 year professional experience in the drug abuse treatment and prevention field includes being the Co-Director of the Haight-Ashbury Drug Treatment Program, being a member of Governor Reagan’s Inter Agency Task Force on Drug Abuse, a member of both the Santa Barbara and the San Diego County Drug Abuse Technical Advisor Committees, and a consultant to Hoffman-LaRoche, Santa Barbara County Schools and the National PTA. He has been recognized by the Santa Barbara Medical Society with the Humanitarian Recognition Award.

Cannabis Case Studies and Clinical Trials as Dr. Mitch Earleywine welcomes Associate Professor Emeritus of Psychiatry at Harvard Medical School Dr. Lester Grinspoon.

Today on Burning Issues Dr. Mitch is Joined by Julie Holland, M.D. Julie is a psychiatrist specializing in psychopharmacology, with a private practice in New York City. She majored in the Biological Basis of Behavior at the University of Pennsylvania and received her M.D. in 1992 from Temple University School of Medicine. At Mount Sinai Medical Center, she completed a residency program in psychiatry, where she created a research project that treated schizophrenics with a new medication. Together they talk about The evidence-base supporting the likelihood of safety and efficacy of cannabis for ADHD in adults and the need for definitive clinical trials. Also, Possible mechanism of action of THC, CBD etc in ADHD, including any basis in science for current working theory that cannabis provides focus through retrograde inhibition of GABA to create more Dopamine Transporter.

Dr. Mitch speaks with Dr. Patel about the many questions asked regarding marijuana doctors and the instructions given by doctors on how to safely use and determine the proper dosage of marijuana

Today on Burning Issues DR. Mich is Joined by Professor Philip Asherson from the Institute of Psychiatry, Psychology & Neuroscience. At King's College London Professor Philip is the head of The ADHD Genetics Group. This group is a research group within the SGDP whose main aim is to identify the genes involved in ADHD and related behavioural traits, and investigate how such genes work together and with environment to influence behaviour.